Skip to content

Efficacy of a combined multi-polar radiofrequency with pulsed electromagnetic field technology for the treatment of vaginal laxity: a double-blinded, randomized, controlled trial

Efficacy of a Combined Multi-polar Radiofrequency with Pulsed Electromagnetic Field Technology for the Treatment of Vaginal Laxity: A Double-blinded, Randomized, Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200803002
Enrollment
32
Registered
2020-08-03
Start date
2018-11-30
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vaginal laxity Multi&#45

Interventions

Treatment group received treatment at an RF energy level up to 55% and a target therapeutic temperature level of 40&#45
41°C for the proximal (closest to the applicator base) pair of electrodes while for the mid and distal (furthest from the applicator base) pairs of electrodes the energy level was adjusted to 65% a
45°C.Duration of each treatment was approximately 15 minutes. ,Sham group received treatment at an RF energy level 0% for all three pairs of electrodes. Duration of each treatment was approximately
(multipolar RF with PEMF) treatment ,Sham treatment.

Sponsors

Division of Dermatology, Ramathibodi Hospital
Lead Sponsor
Division of Dermatology&#44
Collaborator
Ramathibodi Hospital
Collaborator

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria consisted of self-reported of vaginal laxity defined as “very loose”, “moderately loose”, or “slightly loose” assessed by Vaginal Laxity Questionnaire (VLQ) score, normal Papanicolou smear cytology, negative pregnancy test within 2 months, willingness to participate in vaginal intercourse at least two times per month and be either surgically sterilized or willing to use an acceptable method of birth control at least one month before screening and throughout the duration of study

Exclusion criteria

Exclusion criteria: Women were excluded from the trial if they had evidence of pelvic organ prolapse beyond the hymenal ring, an active sexually transmitted disease, urinary tract infection, those with clinically active lesion around vagina, cervix, labia majora, labia minora and clitoris, those with history of surgical vaginal repair, those taking medications known to affect collagen remodeling and healing process (eg. NSAIDS, steroid) within 1 month prior to treatment. However, those subjects who were on oral contraceptives prior to enrollment continued to take these pills throughout the study were not excluded. All pregnant and breastfeeding women, severe or uncontrolled underlying disease, unable to follow-up according to the study protocol led to exclusion of candidates.

Design outcomes

Primary

MeasureTime frame
vaginal laxity 12 weeks (Vaginal Laxity Questionnaire; VLQ)

Secondary

MeasureTime frame
vaginal laxity 12 weeks Brink scale, perineometer, Female Sexual Function Index Questionnaire, Visual Analog Scale, 10-poi

Countries

Thailand

Contacts

Public ContactPenpun Wattanakrai

Faculty of Medicine Ramathibodi Hospital, Mahidol University

maypenpun@gmail.com0818181103

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026